Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease

被引：0
|
作者：
Andrew J. Leidner
Harrell W. Chesson
Philip R. Spradling
Scott D. Holmberg
机构：
[1] Centers for Disease Control and Prevention,Division of Viral Hepatitis
[2] Centers for Disease Control and Prevention,Division of Sexually Transmitted Disease Prevention
来源：
Applied Health Economics and Health Policy | 2017年 / 15卷
关键词：
Supplemental Appendix; Background Mortality; Moderate Fibrosis; Early Stage Liver Disease; Increase Background Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 74
页数：9
相关论文
共 41 条
  • [1] Assessing the Effect of Potential Reductions in Non-Hepatic Mortality on the Estimated Cost-Effectiveness of Hepatitis C Treatment in Early Stages of Liver Disease
    Leidner, Andrew J.
    Chesson, Harrell W.
    Spradling, Philip R.
    Holmberg, Scott D.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2017, 15 (01) : 65 - 74
  • [2] Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease
    Leidner, Andrew J.
    Chesson, Harrell W.
    Xu, Fujie
    Ward, John W.
    Spradling, Philip R.
    Holmberg, Scott D.
    HEPATOLOGY, 2015, 61 (06) : 1860 - 1869
  • [3] COST-EFFECTIVENESS OF HEPATITIS C TREATMENT FOR LEBANESE PATIENTS IN EARLY STAGES OF LIVER DISEASE
    Nasser, S.
    Nader, Abi T.
    Mansour, H.
    VALUE IN HEALTH, 2017, 20 (05) : A78 - A78
  • [4] Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease
    Rustgi, Vinod K.
    Duff, Steve B.
    Elsaid, Mohamed, I
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 347 - 355
  • [5] COST-EFFECTIVENESS OF TREATMENT STRATEGIES INITIATED AT DIFFERENT STAGES OF LIVER FIBROSIS FOR JAPANESE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1
    Suenaga, R.
    Suka, M.
    Hirao, T.
    Ikai, H.
    Hidaka, I
    Sakaida, I
    Ishida, H.
    VALUE IN HEALTH, 2017, 20 (09) : A635 - A635
  • [6] THE IMPACT OF DYNAMIC TRANSMISION MODELING ON THE ESTIMATED COST-EFFECTIVENESS OF TREATMENT FOR CHRONIC HEPATITIS C IN THE UNITED KINGDOM
    Madin-Warburton, M.
    Pitcher, A.
    Martin, N.
    VALUE IN HEALTH, 2016, 19 (07) : A347 - A347
  • [7] Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population
    Chahal, Harinder S.
    Marseille, Elliot A.
    Tice, Jeffrey A.
    Pearson, Steve D.
    Ollendorf, Daniel A.
    Fox, Rena K.
    Kahn, James G.
    JAMA INTERNAL MEDICINE, 2016, 176 (01) : 65 - 73
  • [8] EFFECT OF MORTALITY ON COST-EFFECTIVENESS MODELING OF DISEASE-MODIFYING TREATMENT FOR ALZHEIMER'S DISEASE
    Aye, S.
    Jonsson, L.
    VALUE IN HEALTH, 2022, 25 (12) : S483 - S483
  • [9] Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease
    Aye, Sandar
    Jonsson, Linus
    Gustavsson, Anders
    Tate, Ashley
    Ptacek, Sara Garcia
    Eriksdotter, Maria
    ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING, 2023, 15 (01)
  • [10] Cost-Effectiveness of Noninvasive Liver Fibrosis Tests for Treatment Decisions in Patients With Chronic Hepatitis C
    Tsochatzis, Emmanuel A.
    Crossan, Catriona
    Longworth, Louise
    Gurusamy, Kurinchi
    Rodriguez-Peralvarez, Manolo
    Mantzoukis, Konstantinos
    O'Brien, Julia
    Thalassinos, Evangelos
    Papastergiou, Vassilios
    Noel-Storr, Anna
    Davidson, Brian
    Burroughs, Andrew K.
    HEPATOLOGY, 2014, 60 (03) : 832 - 843
12345